AOD-9604

AOD-9604 is a modified fragment associated with the fat-metabolism region of growth hormone. It is not a GLP-class appetite drug, an injection of full-length GH or an established substitute for either^1,3.

The most informative published experiments distinguish reduced weight gain from weight loss. That difference is essential when interpreting animal results for someone seeking a change in body composition^1,2,3.

Early development sought to retain lipolytic activity while avoiding unwanted full-GH effects. A development review documented early human trials, but did not provide a definitive clinical efficacy result^1,4.

Later human work is documented in a sponsor-associated safety analysis. Its intravenous and oral preparations must remain distinct from a routine subcutaneous catalog product, and a reported favorable average safety profile does not establish clinical weight-loss efficacy^8,9.

The obese-rat study reported increased adipose lipolysis with less body-weight gain over 19 days. The change was not a measured percentage loss of starting body weight¹.

In mice, increased beta-adrenergic receptor expression accompanied metabolic changes, while receptor-knockout experiments complicated a simple direct-receptor explanation. GH-receptor binding and proliferation assays were negative for AOD in the separate experiment^2,3.

A sponsor-associated paper summarizes 6 controlled trials with 893 participants, including intravenous and oral preparations. It focused on safety and tolerability rather than providing a definitive weight-loss efficacy result; the authors' commercial connections and route differences belong in the interpretation⁸.

FDA's advisory-committee assessment describes a 536-participant obesity study that did not find significant weight loss versus placebo. This is an agency summary rather than a separately published efficacy paper, and it materially limits the metabolic promise⁹.

An obese-rat experiment reported more than 50% less weight gain during 19 days, with a gain of 15.8 g compared with 35.6 g in controls. Both groups still gained weight¹.

A mouse fat-oxidation experiment ran for 14 days. Separately, a study in 32 rabbits evaluated intra-articular AOD with or without hyaluronic acid; that route and injury model are different from a systemic metabolic application^3,5.

The human safety analysis reported generally favorable findings for the studied intravenous and oral preparations, with attention to glucose and IGF-I. Its population and exposure limits, sponsor associations and the incomplete safety information identified by FDA do not support a blanket no-risk or glucose-neutral promise for this product^6,8.

FDA highlights immunogenicity, peptide impurities and incomplete human safety information, including uncertain serious-event associations. These issues apply independently of any favorable animal findings⁶.

Human safety research used intravenous or oral preparations, while the rabbit joint study used a local injection. These do not establish a routine human subcutaneous regimen^5,8. Confirm the actual route, final formulation and compatible diluent with the dispensing pharmacy.

The catalog specifies vial content, not a verified final formulation or storage specification. A lyophilized preparation requires the pharmacy-specified compatible diluent; a ready-to-use liquid does not. Follow the dispensing label for refrigeration, light protection and the beyond-use date, and use aseptic technique with a new sterile needle and syringe⁷. Dosing is set by your provider.